IN2014CN00989A - - Google Patents
Info
- Publication number
- IN2014CN00989A IN2014CN00989A IN989CHN2014A IN2014CN00989A IN 2014CN00989 A IN2014CN00989 A IN 2014CN00989A IN 989CHN2014 A IN989CHN2014 A IN 989CHN2014A IN 2014CN00989 A IN2014CN00989 A IN 2014CN00989A
- Authority
- IN
- India
- Prior art keywords
- compounds
- treprostinil
- pah
- prodrugs
- covalent
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 abstract 2
- 229960005032 treprostinil Drugs 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177409 | 2011-08-12 | ||
| EP11195615 | 2011-12-23 | ||
| EP12165508 | 2012-04-25 | ||
| PCT/EP2012/065745 WO2013024052A1 (fr) | 2011-08-12 | 2012-08-10 | Promédicaments à base de tréprostinil lié à un excipient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00989A true IN2014CN00989A (fr) | 2015-04-10 |
Family
ID=46690494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN989CHN2014 IN2014CN00989A (fr) | 2011-08-12 | 2012-08-10 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9561287B2 (fr) |
| EP (1) | EP2741781A1 (fr) |
| JP (1) | JP6092867B2 (fr) |
| KR (1) | KR101997939B1 (fr) |
| CN (1) | CN103857413A (fr) |
| AU (1) | AU2012296954B2 (fr) |
| BR (1) | BR112014003225A2 (fr) |
| CA (1) | CA2843883C (fr) |
| HK (1) | HK1198359A1 (fr) |
| IL (1) | IL230712A (fr) |
| IN (1) | IN2014CN00989A (fr) |
| MX (1) | MX349950B (fr) |
| WO (1) | WO2013024052A1 (fr) |
| ZA (1) | ZA201400977B (fr) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX349950B (es) * | 2011-08-12 | 2017-08-22 | Ascendis Pharma As | Profarmacos de treprostinil enlazados a un portador. |
| CA2868925C (fr) * | 2012-04-25 | 2020-01-21 | Ascendis Pharma A/S | Promedicaments de medicaments comprenant des groupes hydroxyle |
| EP2928501B1 (fr) | 2012-12-07 | 2020-05-06 | Ascendis Pharma A/S | Prodrogues à base de prostanoïdes liés à un support |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| EP3712142B1 (fr) | 2013-01-11 | 2022-07-06 | Corsair Pharma, Inc. | Promédicaments de tréprostinil |
| JP6263604B2 (ja) * | 2013-03-25 | 2018-01-17 | ユナイテッド セラピューティクス コーポレイション | チオールリンカーを持つ、ペグ化型のプロスタサイクリン化合物の製造方法 |
| US9758465B2 (en) | 2013-04-30 | 2017-09-12 | United Therapeutics Corporation | Controlled release pharmaceutical formulations |
| ES2860975T3 (es) | 2013-10-25 | 2021-10-05 | Insmed Inc | Compuestos de prostaciclina |
| TWI685348B (zh) * | 2014-05-08 | 2020-02-21 | 美國禮來大藥廠 | 速效胰島素組合物 |
| ES2908142T3 (es) * | 2014-06-13 | 2022-04-27 | United Therapeutics Corp | Formulaciones de treprostinil |
| JP6561109B2 (ja) * | 2014-07-16 | 2019-08-14 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| AU2015349969B2 (en) | 2014-11-18 | 2020-02-06 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| TWI540121B (zh) | 2014-12-01 | 2016-07-01 | 臺灣永光化學工業股份有限公司 | 曲前列環素二乙醇胺之合成方法及新穎中間體 |
| CA2967899C (fr) * | 2014-12-03 | 2023-09-19 | Steadymed Ltd | Formulations de treprostinil exemptes de conservateur et procedes et dispositifs s'utilisant avec celles-ci |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9643911B2 (en) * | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| EP3400021A1 (fr) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Agonistes de cnp à libération contrôlée présentant une faible liaison à npr-c |
| WO2017118700A1 (fr) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Agonistes cnp à libération contrôlée présentant une meilleure stabilité à nep |
| IL259827B2 (en) | 2016-01-08 | 2025-07-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low initial NPR-B activity |
| CA3007976C (fr) | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Promedicaments du cnp possedant de grands fragments a role de transporteur |
| DK3400019T3 (da) | 2016-01-08 | 2022-10-24 | Ascendis Pharma Growth Disorders As | CNP-prodrugs med bærerbinding ved ringenheden |
| ES3064816T3 (en) | 2016-01-08 | 2026-04-29 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with reduced side-effects |
| MY208384A (en) | 2016-03-01 | 2025-05-05 | Ascendis Pharma Bone Diseases As | Pth prodrugs |
| US11896671B2 (en) | 2016-07-13 | 2024-02-13 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
| RU2757903C2 (ru) | 2016-09-15 | 2021-10-22 | Камурус Аб | Препараты аналогов простациклина |
| US11564974B2 (en) | 2016-09-29 | 2023-01-31 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release CNP agonists |
| HRP20230383T1 (hr) | 2016-09-29 | 2023-07-07 | Ascendis Pharma Bone Diseases A/S | Pth spojevi s malim omjerima maksimalne prema minimalnoj koncentraciji |
| US12453778B2 (en) | 2016-09-29 | 2025-10-28 | Ascendis Pharma Bone Diseases A/S | Incremental dose finding in controlled-release PTH compounds |
| KR102627405B1 (ko) | 2016-09-29 | 2024-01-18 | 아센디스 파마 본 디지즈 에이/에스 | 조절 방출 pth 화합물을 위한 투여 용법 |
| EP3498283A1 (fr) | 2017-12-14 | 2019-06-19 | Ipsol AG | Dérivés glycosidiques de tréprostinil |
| CN112334152A (zh) | 2018-05-18 | 2021-02-05 | 阿森迪斯药物骨疾病股份有限公司 | Pth缀合物的起始剂量 |
| EP3856256A1 (fr) | 2018-09-26 | 2021-08-04 | Ascendis Pharma A/S | Nouveaux conjugués d'hydrogel |
| WO2020064847A1 (fr) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Hydrogels dégradables d'acide hyaluronique |
| WO2020064844A1 (fr) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Traitement d'infections |
| AU2020204785A1 (en) | 2019-01-04 | 2021-06-03 | Ascendis Pharma Oncology Division A/S | Sustained local drug levels for innate immune agonists |
| CA3125488A1 (fr) | 2019-01-04 | 2020-07-09 | Ascendis Pharma Oncology Division A/S | Induction d'une inflammation locale soutenue |
| PH12021551591A1 (en) | 2019-01-04 | 2022-04-18 | Ascendis Pharma Oncology Div A/S | Conjugates of pattern recognition receptor agonists |
| EP3906065B1 (fr) | 2019-01-04 | 2025-04-30 | Ascendis Pharma Oncology Division A/S | Agoniste de prr et son utilisation dans le traitement du cancer |
| MX2021008708A (es) | 2019-02-11 | 2021-09-21 | Ascendis Pharma Growth Disorders As | Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp). |
| MY209748A (en) | 2019-02-11 | 2025-07-31 | Ascendis Pharma Bone Diseases As | Liquid pharmaceutical formulations of pth conjugates |
| CN114072136B (zh) | 2019-04-29 | 2024-11-29 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| WO2020254613A1 (fr) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Composés inhibiteurs de tyrosine kinase à libération contrôlée présentant des propriétés pharmacocinétiques localisées |
| AU2020295725A1 (en) | 2019-06-21 | 2021-12-02 | Ascendis Pharma Oncology Division A/S | Anti-CTLA4 conjugates |
| WO2020254612A1 (fr) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Composés inhibiteurs de tyrosine kinases à libération contrôlée présentant des propriétés pharmacodynamiques localisées |
| WO2020254617A1 (fr) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Composés anti-ctla4 présentant des propriétés pharmacocinétiques localisées |
| WO2020254607A1 (fr) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Composés anti-ctla4 à propriétés pd localisées |
| TW202114660A (zh) | 2019-06-21 | 2021-04-16 | 丹麥商阿仙帝斯製藥公司 | 酪胺酸激酶抑制劑結合物 |
| JP2020011957A (ja) * | 2019-07-22 | 2020-01-23 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| MX2022007371A (es) | 2020-01-13 | 2022-07-12 | Ascendis Pharma Bone Diseases As | Tratamiento del hipoparatiroidismo. |
| EP4146281A1 (fr) | 2020-05-04 | 2023-03-15 | Ascendis Pharma A/S | Irradiation d'hydrogel |
| IL298591A (en) * | 2020-06-09 | 2023-01-01 | United Therapeutics Corp | Pomeryl dictopiperidine prodrugs of treprostinil |
| WO2022064035A1 (fr) | 2020-09-28 | 2022-03-31 | Ascendis Pharma Bone Diseases A/S | Amélioration du bien-être physique et mental de patients atteints d'hypoparathyroïdisme |
| JP7138685B2 (ja) * | 2020-10-26 | 2022-09-16 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| WO2022194195A1 (fr) * | 2021-03-16 | 2022-09-22 | 江苏恒瑞医药股份有限公司 | Dérivé de tréprostinil et son utilisation |
| IL311539A (en) | 2021-09-22 | 2024-05-01 | Ascendis Pharma Bone Diseases As | Long-acting pth compound treatments |
| MX2024006698A (es) | 2021-12-13 | 2024-06-19 | Ascendis Pharma Oncology Div A/S | Tratamientos de cancer con agonistas de los receptores tipo toll 7 y 8 (tlr7/8). |
| WO2023110758A1 (fr) | 2021-12-13 | 2023-06-22 | Ascendis Pharma Growth Disorders A/S | Doses efficaces de conjugués cnp |
| CN116444377A (zh) * | 2022-01-07 | 2023-07-18 | 广州楷石医药有限公司 | 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途 |
| EP4529454A1 (fr) | 2022-05-23 | 2025-04-02 | Ascendis Pharma Growth Disorders A/S | Formulations pharmaceutiques liquides de composés cnp |
| JP2025537527A (ja) | 2022-11-02 | 2025-11-18 | アセンディス ファーマ ボーン ディジージズ エー／エス | ２つのｐｔｈ化合物を含むｐｔｈ治療レジメン |
| WO2024104922A1 (fr) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Procédé d'amélioration de la fonction musculaire squelettique |
| AU2024240722A1 (en) | 2023-03-20 | 2025-09-18 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| IL326658A (en) | 2023-09-04 | 2026-04-01 | Ascendis Pharma Bone Diseases As | PTH treatment in chronic kidney disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| CA1241324A (fr) | 1984-03-08 | 1988-08-30 | Paul A. Aristoff | Derives d'interphenylene carbacycline |
| CA2359652A1 (fr) * | 1999-03-31 | 2000-10-05 | United Therapeutics Corporation | Composes de prostaglandine, compositions et methodes de traitement de maladies vasculaires peripheriques et de l'hypertension pulmonaire |
| PL1620118T3 (pl) * | 2003-04-08 | 2014-11-28 | Yeda Res & Dev | Leki odwracalnie pegylowane |
| ATE441418T1 (de) * | 2003-12-16 | 2009-09-15 | United Therapeutics Corp | Verwendung von treprostinil zur verbesserung der nierenfunktion |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| EP1625856A1 (fr) | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Hydrogel conjugé polymèrique d'une prodrogue |
| JP2010518122A (ja) | 2007-02-09 | 2010-05-27 | ユナイテッド セラピューティクス コーポレーション | 間質性肺疾患および喘息のためのトレプロスチニル処置 |
| SI2173890T1 (sl) * | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| MX344559B (es) | 2008-04-29 | 2016-12-20 | Ascendis Pharma As | Compuestos de hormona de crecimiento humana recombinante unidos al peg. |
| WO2010014258A2 (fr) * | 2008-08-01 | 2010-02-04 | Nektar Therapeutics Al, Corporation | Conjugués possédant une liaison libérable |
| AU2009282413B2 (en) * | 2008-08-11 | 2014-07-17 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| WO2010033240A2 (fr) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymères à base de glucide pour administration de médicaments et leurs conjugués |
| WO2010068754A2 (fr) * | 2008-12-10 | 2010-06-17 | Paka Pulmonary Pharmaceuticals, Inc. | Procédés et compositions pour la délivrance de médicaments aux poumons |
| WO2010144508A1 (fr) * | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Polypeptides de régulation du glucose et leurs procédés de production et d'utilisation |
| CA2769162C (fr) * | 2009-07-31 | 2017-12-05 | Ascendis Pharma As | Hydrogels insolubles dans l?eau a base de polyethylene glycol biodegradable |
| EP2485767A1 (fr) * | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Promédicaments à base de palipéridone liée à un support |
| MX349950B (es) * | 2011-08-12 | 2017-08-22 | Ascendis Pharma As | Profarmacos de treprostinil enlazados a un portador. |
-
2012
- 2012-08-10 MX MX2014001497A patent/MX349950B/es active IP Right Grant
- 2012-08-10 EP EP12748194.3A patent/EP2741781A1/fr not_active Withdrawn
- 2012-08-10 CA CA2843883A patent/CA2843883C/fr not_active Expired - Fee Related
- 2012-08-10 WO PCT/EP2012/065745 patent/WO2013024052A1/fr not_active Ceased
- 2012-08-10 CN CN201280049725.9A patent/CN103857413A/zh active Pending
- 2012-08-10 US US14/238,437 patent/US9561287B2/en active Active
- 2012-08-10 JP JP2014524413A patent/JP6092867B2/ja not_active Expired - Fee Related
- 2012-08-10 BR BR112014003225A patent/BR112014003225A2/pt not_active Application Discontinuation
- 2012-08-10 HK HK14111870.6A patent/HK1198359A1/xx unknown
- 2012-08-10 IN IN989CHN2014 patent/IN2014CN00989A/en unknown
- 2012-08-10 AU AU2012296954A patent/AU2012296954B2/en not_active Ceased
- 2012-08-10 KR KR1020147006343A patent/KR101997939B1/ko not_active Expired - Fee Related
-
2014
- 2014-01-29 IL IL230712A patent/IL230712A/en active IP Right Grant
- 2014-02-10 ZA ZA2014/00977A patent/ZA201400977B/en unknown
-
2017
- 2017-01-27 US US15/418,180 patent/US10729778B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6092867B2 (ja) | 2017-03-08 |
| CA2843883C (fr) | 2020-04-28 |
| US20140296150A1 (en) | 2014-10-02 |
| KR20140070545A (ko) | 2014-06-10 |
| HK1198359A1 (en) | 2015-04-10 |
| IL230712A0 (en) | 2014-03-31 |
| BR112014003225A2 (pt) | 2017-03-01 |
| EP2741781A1 (fr) | 2014-06-18 |
| MX2014001497A (es) | 2014-04-25 |
| AU2012296954A1 (en) | 2014-02-20 |
| US9561287B2 (en) | 2017-02-07 |
| WO2013024052A1 (fr) | 2013-02-21 |
| US20190105400A1 (en) | 2019-04-11 |
| AU2012296954B2 (en) | 2016-09-15 |
| MX349950B (es) | 2017-08-22 |
| CA2843883A1 (fr) | 2013-02-21 |
| CN103857413A (zh) | 2014-06-11 |
| JP2014527050A (ja) | 2014-10-09 |
| IL230712A (en) | 2017-08-31 |
| US10729778B2 (en) | 2020-08-04 |
| ZA201400977B (en) | 2017-11-29 |
| KR101997939B1 (ko) | 2019-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN00989A (fr) | ||
| PH12017501426A1 (en) | Derivatives of betulin | |
| MY187718A (en) | Pharmaceutical formulations | |
| WO2012122340A8 (fr) | Activateurs de guanylate cyclase solubles | |
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| MX2015005286A (es) | Procedimiento para la preparación de derivados del ácido biliar. | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| PH12014502733A1 (en) | Neprilysin inhibitors | |
| MX2014004196A (es) | Citramida de rasagilina. | |
| TN2014000112A1 (en) | Ep1 receptor ligands | |
| IN2012DN02139A (fr) | ||
| TN2011000585A1 (en) | Lxr modulators | |
| WO2010150211A3 (fr) | Utilisation de dérivés d'indoles dans le traitement du cancer | |
| MX2011011776A (es) | Nuevos profarmacos de triptolite. | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| WO2012104823A3 (fr) | Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives | |
| IN2014CN04449A (fr) | ||
| WO2013093931A3 (fr) | Nouveaux promédicaments de médicaments phénoliques | |
| IN2013DN02555A (fr) | ||
| MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
| WO2014030173A3 (fr) | Procédé amélioré pour préparer de l'atazanavir disulfate | |
| WO2012176163A3 (fr) | Composés pour le traitement de cancers associés à un papillomavirus humain | |
| MX2013002656A (es) | Nuevo proceso. | |
| WO2013074905A3 (fr) | Composés, compositions, compositions pharmaceutiques et procédés d'utilisation |